Orthocell has announced the appointment of Mr. John Van Der Wielen as Orthocell’s new independent Non-Executive Chairman, effective June 1, 2023.
Mr. Van Der Wielen is a globally recognised executive with a passion for supporting innovative life science companies and for enhancing Australia’s capacity to translate local innovations into products that make a difference to clinical practice and patients’ lives.
He has over 35 years’ international experience in wealth management, private banking, investments, and insurance, and has held senior executive positions with several national and global financial services groups. Most recently Mr. Van Der Wielen was CEO and MD of HBF Health Ltd for over five years.
John Van Der Wielen said:
“I am very excited to be joining the senior leadership team at Orthocell at this pivotal stage in the Company’s development. I have been monitoring the Company’s significant progress including its recent landmark licensing deal with BioHorizons. I believe Orthocell is now extremely well placed to drive shareholder value by actively supporting distribution partners to ramp up sales in existing and additional international markets, and to advance the commercialisation of its truly unique regenerative medicine portfolio.”
Click here to read today’s ASX release.